IMPORTANCE: Many patients with peripheral artery disease (PAD) have walking impairment despite therapy. Experimental studies in animals demonstrate improved perfusion in ischemic hind limb after mobilization of bone marrow progenitor cells (PCs), but whether this is effective in patients with PAD is unknown. OBJECTIVE: To investigate whether therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF) improves exercise capacity in patients with intermittent claudication. DESIGN, SETTING, AND PARTICIPANTS: In a phase 2 double-blind, placebo-controlled study, 159 patients (median [SD] age, 64 [8] years; 87% male, 37% with diabetes) with intermittent claudication were enrolled at medical centers affiliated with Emory University in Atlanta, Georgia, between January 2010 and July 2012. INTERVENTIONS: Participants were randomized (1:1) to received 4 weeks of subcutaneous injections of GM-CSF (leukine), 500 μg/day 3 times a week, or placebo. Both groups were encouraged to walk to claudication daily. MAIN OUTCOMES AND MEASURES: The primary outcome was peak treadmill walking time (PWT) at 3 months. Secondary outcomes were PWT at 6 months and changes in circulating PC levels, ankle brachial index (ABI), and walking impairment questionnaire (WIQ) and 36-item Short-Form Health Survey (SF-36) scores. RESULTS: Of the 159 patients randomized, 80 were assigned to the GM-CSF group. The mean (SD) PWT at 3 months increased in the GM-CSF group from 296 (151) seconds to 405 (248) seconds (mean change, 109 seconds [95% CI, 67 to 151]) and in the placebo group from 308 (161) seconds to 376 (182) seconds (change of 56 seconds [95% CI, 14 to 98]), but this difference was not significant (mean difference in change in PWT, 53 seconds [95% CI, -6 to 112], P = .08). At 3 months, compared with placebo, GM-CSF improved the physical functioning subscore of the SF-36 questionnaire by 11.4 (95% CI, 6.7 to 16.1) vs 4.8 (95% CI, -0.1 to 9.6), with a mean difference in change for GM-CSF vs placebo of 7.5 (95% CI, 1.0 to 14.0; P = .03). Similarly, the distance score of the WIQ improved by 12.5 (95% CI, 6.4 to 18.7) vs 4.8 (95% CI, -0.2 to 9.8) with GM-CSF compared with placebo (mean difference in change, 7.9 [95% CI, 0.2 to 15.7], P = .047). There were no significant differences in the ABI, WIQ distance and speed scores, claudication onset time, or mental or physical component scores of the SF-36 between the groups. CONCLUSIONS AND RELEVANCE: Therapy with GM-CSF 3 times a week did not improve treadmill walking performance at the 3-month follow-up. The improvements in some secondary outcomes with GM-CSF suggest that it may warrant further study in patients with claudication. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01041417.
IMPORTANCE: Many patients with peripheral artery disease (PAD) have walking impairment despite therapy. Experimental studies in animals demonstrate improved perfusion in ischemic hind limb after mobilization of bone marrow progenitor cells (PCs), but whether this is effective in patients with PAD is unknown. OBJECTIVE: To investigate whether therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF) improves exercise capacity in patients with intermittent claudication. DESIGN, SETTING, AND PARTICIPANTS: In a phase 2 double-blind, placebo-controlled study, 159 patients (median [SD] age, 64 [8] years; 87% male, 37% with diabetes) with intermittent claudication were enrolled at medical centers affiliated with Emory University in Atlanta, Georgia, between January 2010 and July 2012. INTERVENTIONS: Participants were randomized (1:1) to received 4 weeks of subcutaneous injections of GM-CSF (leukine), 500 μg/day 3 times a week, or placebo. Both groups were encouraged to walk to claudication daily. MAIN OUTCOMES AND MEASURES: The primary outcome was peak treadmill walking time (PWT) at 3 months. Secondary outcomes were PWT at 6 months and changes in circulating PC levels, ankle brachial index (ABI), and walking impairment questionnaire (WIQ) and 36-item Short-Form Health Survey (SF-36) scores. RESULTS: Of the 159 patients randomized, 80 were assigned to the GM-CSF group. The mean (SD) PWT at 3 months increased in the GM-CSF group from 296 (151) seconds to 405 (248) seconds (mean change, 109 seconds [95% CI, 67 to 151]) and in the placebo group from 308 (161) seconds to 376 (182) seconds (change of 56 seconds [95% CI, 14 to 98]), but this difference was not significant (mean difference in change in PWT, 53 seconds [95% CI, -6 to 112], P = .08). At 3 months, compared with placebo, GM-CSF improved the physical functioning subscore of the SF-36 questionnaire by 11.4 (95% CI, 6.7 to 16.1) vs 4.8 (95% CI, -0.1 to 9.6), with a mean difference in change for GM-CSF vs placebo of 7.5 (95% CI, 1.0 to 14.0; P = .03). Similarly, the distance score of the WIQ improved by 12.5 (95% CI, 6.4 to 18.7) vs 4.8 (95% CI, -0.2 to 9.8) with GM-CSF compared with placebo (mean difference in change, 7.9 [95% CI, 0.2 to 15.7], P = .047). There were no significant differences in the ABI, WIQ distance and speed scores, claudication onset time, or mental or physical component scores of the SF-36 between the groups. CONCLUSIONS AND RELEVANCE: Therapy with GM-CSF 3 times a week did not improve treadmill walking performance at the 3-month follow-up. The improvements in some secondary outcomes with GM-CSF suggest that it may warrant further study in patients with claudication. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01041417.
Authors: Niels van Royen; Stephan H Schirmer; Bektas Atasever; Casper Y H Behrens; Dirk Ubbink; Eva E Buschmann; Michiel Voskuil; Pieter Bot; Imo Hoefer; Reinier O Schlingemann; Bart J Biemond; J G Tijssen; Christoph Bode; Wolfgang Schaper; Jacques Oskam; Dink A Legemate; Jan J Piek; Ivo Buschmann Journal: Circulation Date: 2005-08-08 Impact factor: 29.690
Authors: F Bussolino; J M Wang; P Defilippi; F Turrini; F Sanavio; C J Edgell; M Aglietta; P Arese; A Mantovani Journal: Nature Date: 1989-02-02 Impact factor: 49.962
Authors: F Bussolino; M Ziche; J M Wang; D Alessi; L Morbidelli; O Cremona; A Bosia; P C Marchisio; A Mantovani Journal: J Clin Invest Date: 1991-03 Impact factor: 14.808
Authors: Veerappan Subramaniyam; Edmund K Waller; Jonathan R Murrow; Amita Manatunga; Sagar Lonial; Karthikeswar Kasirajan; Diane Sutcliffe; Wayne Harris; W Robert Taylor; R Wayne Alexander; Arshed A Quyyumi Journal: Am Heart J Date: 2009-07 Impact factor: 4.749
Authors: T A Lane; P Law; M Maruyama; D Young; J Burgess; M Mullen; M Mealiffe; L W Terstappen; A Hardwick; M Moubayed Journal: Blood Date: 1995-01-01 Impact factor: 22.113
Authors: Ibhar Al Mheid; Salim S Hayek; Yi-An Ko; Faysal Akbik; Qunna Li; Nima Ghasemzadeh; Greg S Martin; Qi Long; Muhammad Hammadah; A Maziar Zafari; Viola Vaccarino; Edmund K Waller; Arshed A Quyyumi Journal: Circ Res Date: 2016-07-19 Impact factor: 17.367
Authors: Mary M McDermott; Luigi Ferrucci; Lu Tian; Jack M Guralnik; Donald Lloyd-Jones; Melina R Kibbe; Tamar S Polonsky; Kathryn Domanchuk; James H Stein; Lihui Zhao; Doris Taylor; Christopher Skelly; William Pearce; Harris Perlman; Walter McCarthy; Lingyu Li; Ying Gao; Robert Sufit; Christina L Bloomfield; Michael H Criqui Journal: JAMA Date: 2017-12-05 Impact factor: 56.272
Authors: Amish N Raval; Eric G Schmuck; Girma Tefera; Cathlyn Leitzke; Cassondra Vander Ark; Derek Hei; John M Centanni; Ranil de Silva; Jill Koch; Richard G Chappell; Peiman Hematti Journal: Cytotherapy Date: 2014-09-18 Impact factor: 5.414
Authors: S Fadilah Abdul Wahid; Nor Azimah Ismail; Wan Fariza Wan Jamaludin; Nor Asiah Muhamad; Muhammad Khairul Azaham Abdul Hamid; Hanafiah Harunarashid; Nai Ming Lai Journal: Cochrane Database Syst Rev Date: 2018-08-29
Authors: Rana Saber; Kiang Liu; Luigi Ferrucci; Michael H Criqui; Lihui Zhao; Lu Tian; Jack M Guralnik; Yihua Liao; Kathryn Domanchuk; Melina R Kibbe; David Green; Harris Perlman; Mary M McDermott Journal: Vasc Med Date: 2015-08-31 Impact factor: 3.239